Publications by authors named "Debra Zack"

Claim this Profile
K
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective.
Elena W Y Hsieh, James B Chung, Afsah Amin, Anca D Askanase, Beatrix Bartok, Debra Zack

RMD Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Joan T Merrill, Joel Guthridge, Miles Smith, Joshua June, Fotios Koumpouras, Debra J Zack

Arthritis Rheumatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.
Cory A Perugino, Zachary S Wallace, Debra J Zack, Shauna M Quinn, Allen Poma

Lancet Rheumatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
Tyler O'Malley, Fenglong Xie, Yujie Su, Cassie Clinton, Debra J Zack

J Manag Care Spec Pharm· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Complement Activation in SLE.
Arthur Weinstein, Roberta V Alexander, Debra J Zack

Curr Rheumatol Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
William Stohl, Joan T Merrill, R John Looney, Jill Buyon, Daniel J Wallace, Debra J Zack

Arthritis Res Ther· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: 'Impact of gender on outcomes in ankylosing spondylitis' by Feldtkeller et al.
Irene van der Horst-Bruinsma, Debra Zack, Annette Szumski, Andrew S Koenig

Ann Rheum Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort.
Joseph A Markenson, Andrew S Koenig, Jing Yuan Feng, Sandeep Chaudhari, Debra J Zack

J Clin Rheumatol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy.
Mohammed Hammoudeh, Debra J Zack, Wenzhi Li, V Michelle Stewart, Andrew S Koenig

J Int Med Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.
Irene E van der Horst-Bruinsma, Debra Jeske Zack, Annette Szumski, Andrew S Koenig

Ann Rheum Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.
Vibeke Strand, Veronika Sharp, Andrew S Koenig, Grace Park, Yifei Shi, Debra J Zack

Ann Rheum Dis· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease.
Hailing Hsu, Sanjay D Khare, Frances Lee, Kent Miner, Yi-Ling Hu, Debra J Zack

Clin Exp Rheumatol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review.
Claire Bombardier, Marco Barbieri, Anju Parthan, Debra J Zack, Valery Walker

Ann Rheum Dis· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee.
Stanley B Cohen, Susanna Proudman, Alan J Kivitz, Francis X Burch, John P Donohue, Debra J Zack

Arthritis Res Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.
Brad Bolon, Marina Stolina, Caroline King, Scot Middleton, Jill Gasser, Debra Zack

J Biomed Biotechnol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis.
Mario H Cardiel, Paul P Tak, William Bensen, Francis X Burch, Sarka Forejtova, Debra J Zack

Arthritis Res Ther· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of worldwide pediatric malignancies reported after exposure to etanercept.
Peter McCroskery, Carol A Wallace, Daniel J Lovell, Scott Stryker, Nataliya Chernyukhin, Debra J Zack

Pediatr Rheumatol Online J· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Marina Stolina, Georg Schett, Denise Dwyer, Steven Vonderfecht, Scot Middleton, Debra Zack

Arthritis Res Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus.
Shelley Sims Belouski, Daniel Wallace, Michael Weisman, Mariko Ishimori, Lisa Hendricks, Debra Zack

Cytometry B Clin Cytom· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.
Georg Schett, Marina Stolina, Denise Dwyer, Debra Zack, Stefan Uderhardt

Arthritis Rheum· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.
Marina Stolina, Brad Bolon, Scot Middleton, Denise Dwyer, Heather Brown, Debra Zack

J Clin Immunol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.
Marina Stolina, Brad Bolon, Denise Dwyer, Scot Middleton, Diane Duryea, Debra J Zack

Biomarkers· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, Christina Boucher, Lilly Chai, Debra Zack

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential (1).
Debra Jeske Zack, David Isenberg

Lupus· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
Marina Stolina, Denise Dwyer, Michael S Ominsky, Timothy Corbin, Gwyneth Van, Debra J Zack

J Immunol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis